Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis.

The Journal of experimental medicine - 7 Dec 2020

Fichtner Miriam L, Vieni Casey, Redler Rachel L, Kolich Ljuvica, Jiang Ruoyi, Takata Kazushiro, Stathopoulos Panos, Suarez Pablo A, Nowak Richard J, Burden Steven J, Ekiert Damian C, O'Connor Kevin C

Abstract excerpt

Pathogenic muscle-specific tyrosine kinase (MuSK)-specific IgG4 autoantibodies in autoimmune myasthenia gravis (MG) are functionally monovalent as a result of Fab-arm exchange. The development of these unique autoantibodies is not well understood. We examined MG patient-derived monoclonal autoantibodies (mAbs), their corresponding germline-encoded unmutated common ancestors (UCAs), and monovalent antigen-binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Affinity
Share to Autoantigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fab Fragments

Share to Immunoglobulin G

Share to Myasthenia Gravis

Share to Protein Domains

Share to Receptor Protein-Tyrosine Kinases

Share to Receptors, Cholinergic

Source

Open in PubMed Open full text

Identifiers

PMID: 32820331
DOI: 10.1084/jem.20200513
PMCID: PMC7953735

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis.PMID 32820331Read ↗

Self-antigen driven affinity maturation is required for pathogenic monovalent IgG4 autoantibody developmentSemantic proximity Read ↗

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravisSemantic proximity Read ↗

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravisSemantic proximity Read ↗

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapySemantic proximity Read ↗

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapySemantic proximity Read ↗

MuSK antibodies differently affect the MuSK signaling cascade depending on valency and epitope specificitySemantic proximity Read ↗

Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep SequencingSemantic proximity Read ↗

Isolation and characterization of rare circulating autoantibody-producing cells from patients with muscle-specific kinase myasthenia gravisSemantic proximity Read ↗

Myasthenia thymus reprograms class-switched B cells into BAFF-dependent survivorsSemantic proximity Read ↗

Selective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravisSemantic proximity Read ↗

Elevated N-glycosylation of immunoglobulin G variable regions in myasthenia gravis highlights a commonality across autoantibody-associated diseasesSemantic proximity Read ↗

B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.